Averna Therapeutics develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.
Averna Therapeutics has raised $85.0M in total funding. The most recent round was Series A. The last funding was announced in June 2024.
Averna Therapeutics's investors include Insight Venture Management, LLC., OrbiMed, Invus, Innovation Endeavors, JP Morgan.
Averna Therapeutics is headquartered in Boston, United States.
Averna Therapeutics develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.
Averna Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Averna Therapeutics — Funding & Investors." VCBacked, June 25, 2024, https://www.vcbacked.co/company/averna-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). Averna Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/averna-therapeutics
{{cite web |title=Averna Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/averna-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated